In an unusual move, Sandoz is no longer cooperating with a U.K. industry trade group following a dispute over allegations that the company inappropriately marketed a biosimilar medicine.
At issue was an anonymous complaint filed in May 2023 by a physician who contended that Sandoz unfairly attempted to promote a biosimilar version of Tysabri for treating multiple sclerosis as an affordable option. The company was accused of providing skewed and incomplete cost information and did so before regulators issued marketing authorization, according to a report by the Prescription Medicines Code of Practice Authority.
The PMCPA, which is a self-regulatory body overseen by the Association of the British Pharmaceutical Industry, subsequently determined in February that the company breached several voluntary codes governing business practices. However, Sandoz rejected the findings. But instead of appealing, the company decided it would no longer “accept the jurisdiction” of PMCPA findings.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect